Autologous chimeric antigen receptor (CAR) T cells have changed the therapeutic
landscape in haematological malignancies. Nevertheless, the use of allogeneic CAR T cells …

Chimeric antigen receptor (CAR) T cell therapy has emerged as one of the major
breakthroughs in cancer immunotherapy in the last decade. Outstanding results in …

Chimeric antigen receptor (CAR) T cell therapy has shown impressive clinical efficacy in B
cell malignancies and multiple myeloma, leading to the approval of six CAR T cell products …

The advent of chimeric antigen receptor T cells (CAR-T cells) has made a tremendous
revolution in the era of cancer immunotherapy, so that since 2017 eight CAR-T cell products …

Gamma delta (γδ) T cells recently emerged as an attractive candidate for cancer
immunotherapy treatments due to their inherent cytotoxicity against both hematological and …

Genome editing holds the potential for curative treatments of human disease, however,
clinical realization has proven to be a challenging journey with incremental progress made …

Since the first allogeneic hematopoietic stem cell transplantation (HCT) was performed by
Dr. E. Donnall Thomas in 1957, the field has advanced with new stem cell sources, immune …

Background Although chimeric antigen receptor T (CAR-T) cells have been proven to be an
effective way of treating B cell malignancies, a lot of patients could not benefit from it …

Opinion statement The therapeutic armamentarium has significantly expanded since the
approval of various CD19-targeting chimeric antigen receptor T cell (CAR-T) therapies in …

Biomedical research has witnessed significant strides in manufacturing chimeric antigen
receptor T cell (CAR-T) therapies, marking a transformative era in cellular immunotherapy …